897016-26-1

KX2?361 significantly delays progression of orthotopic GL261 brain tumors and produces long?term survival^[1].
KX2-361 demonstrates appreciable brain penetration when dosed orally to mice (20 mg/kg), with a brain Cmax of 4025±319 ng/g observed 15 min post-dosing and an overall exposure (AUClast) of 5044±355 h ng/g^[1].